OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Anti-angiogenic Therapy or Immunotherapy for Elderly Cancer Patients
Submission Deadline: June 15, 2023 (Open) Submit Now
Junfeng Shi, PhD, MD, Associate professor
Nanjing First Hospital, Nanjing Medical University. Tel.: +86-18951670344
Research Interests: Cancer; Chemotherapy; Drug-resistance; Immunotherapy; Methylation; etc
About This Topic
As people live longer, the incidence of malignant tumors is increasing, which negatively affects individuals and families.
Chemotherapy is often used to treat advanced malignant tumors. Unfortunately, chemotherapy is often not tolerated by the elderly population, and bring large side effects, so to a large extent can not get better treatment, to the elderly both physical and psychological pain. With the application of antiangiogenic drugs and immune drugs, the treatment of “chemotherapeutic” has been accepted by more and more elderly people. While enjoying better therapeutic effects, it also brings better quality of life to the elderly. The new treatment mode has brought more healthy life to the elderly.
It is hoped that the mode of anti-angiogenesis and immunotherapy for malignant tumors can be popularized among the elderly, and more scholars with therapeutic experience will discuss this topic together to improve the health of elderly cancer patients around the world.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.